Cell Culture Systems and Drug Targets for Hepatitis A Virus Infection.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
12 05 2020
Historique:
received: 04 04 2020
revised: 09 05 2020
accepted: 10 05 2020
entrez: 16 5 2020
pubmed: 16 5 2020
medline: 18 2 2021
Statut: epublish

Résumé

Hepatitis A virus (HAV) infection is one of the major causes of acute hepatitis, and this infection occasionally causes acute liver failure. HAV infection is associated with HAV-contaminated food and water as well as sexual transmission among men who have sex with men. Although an HAV vaccine has been developed, outbreaks of hepatitis A and life-threatening severe HAV infections are still observed worldwide. Therefore, an improved HAV vaccine and anti-HAV drugs for severe hepatitis A should be developed. Here, we reviewed cell culture systems for HAV infection, and other issues. This review may help with improving the HAV vaccine and developing anti-HAV drugs.

Identifiants

pubmed: 32408660
pii: v12050533
doi: 10.3390/v12050533
pmc: PMC7291253
pii:
doi:

Substances chimiques

Antiviral Agents 0
Viral Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Références

Biochem Biophys Res Commun. 2004 May 28;318(2):341-5
pubmed: 15120607
J Virol. 2008 Oct;82(20):10118-28
pubmed: 18684812
Antimicrob Agents Chemother. 1990 Jun;34(6):1112-7
pubmed: 2168143
J Med Virol. 1987 May;22(1):57-66
pubmed: 3035080
Med Res Rev. 2014 Sep;34(5):895-917
pubmed: 23722879
Biochem Biophys Res Commun. 2015 Mar 20;458(4):908-12
pubmed: 25704089
Virus Res. 1993 May;28(2):187-94
pubmed: 8391192
Vaccine. 1992;10 Suppl 1:S36-9
pubmed: 1335656
J Clin Microbiol. 1986 Mar;23(3):434-40
pubmed: 3007565
Int J Med Sci. 2018 Jul 30;15(11):1153-1159
pubmed: 30123052
Virol J. 2010 Sep 03;7:212
pubmed: 20815893
mBio. 2016 Dec 6;7(6):
pubmed: 27923925
J Virol. 2002 Feb;76(3):1171-80
pubmed: 11773393
Hepatol Res. 2010 Apr 1;40(4):415-23
pubmed: 20561355
Nat Immunol. 2001 Dec;2(12):1109-16
pubmed: 11725301
J Gen Virol. 1988 Aug;69 ( Pt 8):2129-34
pubmed: 2841419
J Virol. 1987 Oct;61(10):3035-9
pubmed: 3041024
Cold Spring Harb Perspect Med. 2018 Oct 1;8(10):
pubmed: 29530949
J Med Virol. 1986 May;19(1):23-31
pubmed: 3009703
Res Virol. 1991 Jul-Aug;142(4):261-70
pubmed: 1665574
Nat Immunol. 2005 May;6(5):447-54
pubmed: 15793575
Acta Virol. 1993 Aug;37(4):209-22
pubmed: 7905235
J Virol. 1991 Apr;65(4):2056-65
pubmed: 1705995
PLoS Pathog. 2011 Sep;7(9):e1002169
pubmed: 21931545
J Virol. 2006 May;80(9):4633-9
pubmed: 16611923
J Virol. 2014 Sep 1;88(17):10252-8
pubmed: 24920812
Hepatol Res. 2012 Mar;42(3):248-53
pubmed: 22151794
Virology. 1995 Oct 1;212(2):686-97
pubmed: 7571438
J Virol. 1985 Nov;56(2):579-88
pubmed: 2997478
Proc Soc Exp Biol Med. 1979 Feb;160(2):213-21
pubmed: 217023
J Virol. 1994 Feb;68(2):1066-74
pubmed: 8289336
J Virol. 1992 Feb;66(2):650-4
pubmed: 1309907
Antiviral Res. 1986 Mar;6(2):103-12
pubmed: 3010855
J Virol. 1996 Nov;70(11):7948-57
pubmed: 8892918
J Clin Transl Hepatol. 2015 Sep 28;3(3):205-10
pubmed: 26623267
Proc Natl Acad Sci U S A. 1987 Apr;84(8):2497-501
pubmed: 3031686
Indian J Gastroenterol. 2015 Nov;34(6):448-52
pubmed: 26589230
Microbiol Immunol. 2020 May;64(5):392-395
pubmed: 32052883
J Virol. 2006 Feb;80(3):1352-60
pubmed: 16415012
Nature. 2013 Apr 18;496(7445):367-71
pubmed: 23542590
Hepatol Int. 2019 Mar;13(2):103-109
pubmed: 30539517
J Virol. 1994 Aug;68(8):5253-63
pubmed: 8035522
J Infect Chemother. 2020 Feb;26(2):282-285
pubmed: 31543437
J Gen Virol. 2002 Sep;83(Pt 9):2183-2192
pubmed: 12185272
Lancet. 1989 May 13;1(8646):1039-41
pubmed: 2565998
Jpn J Infect Dis. 2019 Jan 23;72(1):44-48
pubmed: 30270252
Clin Infect Dis. 2018 Oct 30;67(10):1477-1492
pubmed: 30215672
Infection. 1979;7(6):303-5
pubmed: 232698
mBio. 2017 Sep 5;8(5):
pubmed: 28874468
Biochem Biophys Res Commun. 2015 Oct 23;466(3):567-71
pubmed: 26388050
J Virol. 1991 Nov;65(11):5828-38
pubmed: 1656072
J Virol Methods. 1987 Nov;18(2-3):193-203
pubmed: 2828401
Virus Res. 2002 Oct;89(1):75-88
pubmed: 12367752
PLoS One. 2014 Jul 07;9(7):e101993
pubmed: 24999657
Virology. 1994 Oct;204(1):60-8
pubmed: 8091685
FEBS J. 2019 Feb;286(4):765-787
pubmed: 30461192
Elife. 2019 Feb 25;8:
pubmed: 30801249
Viral Immunol. 2012 Oct;25(5):379-86
pubmed: 23035851
Eur J Med Chem. 2019 Apr 15;168:447-460
pubmed: 30844608
Infect Immun. 1981 Apr;32(1):388-93
pubmed: 6260685
J Virol. 2006 Jun;80(11):5599-610
pubmed: 16699041
MMWR Morb Mortal Wkly Rep. 2019 May 10;68(18):413-415
pubmed: 31071072
Biochem Biophys Res Commun. 2005 May 20;330(4):1217-23
pubmed: 15823573
Hepatol Res. 2012 Aug;42(8):828-34
pubmed: 22776552
Nat Med. 2005 Jul;11(7):791-6
pubmed: 15951748
J Virol. 2018 Apr 13;92(9):
pubmed: 29437974
Antimicrob Agents Chemother. 2005 Sep;49(9):3833-41
pubmed: 16127060
J Med Virol. 1981;7(3):233-9
pubmed: 6270280
EMBO J. 1996 Aug 15;15(16):4282-96
pubmed: 8861957
Viruses. 2016 Sep 20;8(9):
pubmed: 27657111
Antiviral Res. 1995 Sep;28(1):69-80
pubmed: 8585761
J Virol. 1994 Sep;68(9):6064-8
pubmed: 8057483
J Clin Microbiol. 1983 May;17(5):834-9
pubmed: 6306048
Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9294-9
pubmed: 15939869
Jpn J Infect Dis. 2019 Jan 23;72(1):53-55
pubmed: 30175732
J Virol. 2005 Mar;79(5):2950-5
pubmed: 15709014
J Med Virol. 1990 Jun;31(2):155-60
pubmed: 2167349
J Virol. 2010 Aug;84(16):8342-7
pubmed: 20534860
Med Microbiol Immunol. 1981;170(2):83-9
pubmed: 6275251
J Gen Virol. 1991 Jul;72 ( Pt 7):1677-83
pubmed: 1649901
Biochem Biophys Res Commun. 2005 Jun 3;331(2):621-9
pubmed: 15850805
J Med Virol. 1981;7(4):273-86
pubmed: 6278066
J Virol. 1994 Jan;68(1):548-54
pubmed: 8254770
Sci Rep. 2016 Nov 03;6:35962
pubmed: 27808108
J Virol. 2019 May 15;93(11):
pubmed: 31092684
BMC Cell Biol. 2015 Feb 27;16:4
pubmed: 25886889

Auteurs

Tatsuo Kanda (T)

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.

Reina Sasaki (R)

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.

Ryota Masuzaki (R)

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.

Naoki Matsumoto (N)

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.

Masahiro Ogawa (M)

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.

Mitsuhiko Moriyama (M)

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH